📖

C3 — Complement Component 3

wiki page Created: 2026-04-02T20:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-c3

Related Entities

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

📊 Evidence Profile

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

177

Outgoing

117

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Linked Artifacts (291)

mentions🧪SASP-Mediated Complement Cascade Amplification90%

related🧪SASP-Mediated Complement Cascade Amplification90%

mentions🧫bEV-mediated synaptic pruning via C1q-C3 pathway80%

mentions🧪SASP-Mediated Complement Cascade Amplification80%

mentions🧫Proposed experiment from debate on Synaptic pruning by micro70%

mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress70%

mentions🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?70%

related🔬Neuroinflammation and microglial priming in early Alzheimer&70%

mentions🧫Experiment: Autoimmune Hypothesis Testing in AD70%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des70%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 70%

related🧫Experiment: Autoimmune Hypothesis Testing in AD70%

mentions🧫Proposed experiment from debate on Senolytics targeting p16/70%

related🧫Proposed experiment from debate on Synaptic pruning by micro70%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?70%

mentions🧫Normal Aging to Alzheimer's Disease Transition Trigger 70%

related🧫Proposed experiment from debate on Senolytics targeting p16/70%

mentions🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des70%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress70%

related🔬What is the relative contribution of connexin-43 gap junctio70%

mentions🔬What are the mechanisms underlying senolytic therapy for age70%

mentions🔬What are the mechanisms underlying senolytic therapy for age63%

related🧫Normal Aging to Alzheimer's Disease Transition Trigger 63%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress63%

related🧫Viral and Post-Infectious Mechanisms in ALS — Experiment Des63%

related🧫Experiment: Autoimmune Hypothesis Testing in AD63%

related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?63%

related🧫Proposed experiment from debate on Senolytics targeting p16/63%

related🧫Proposed experiment from debate on Synaptic pruning by micro63%

see_also📖APP Gene Dosage Reduction Therapy for Down Syndrome60%

see_also📖CR2 (Complement Receptor Type 2)60%

see_also📖TGF-beta Signaling Therapies for Neurodegeneration60%

see_also📖Biomarkers of Alzheimer Disease60%

see_also📖Senolytic Therapeutics: Investment Landscape Analysis60%

see_also📖Sage Therapeutics60%

see_also📖therapeutics60%

see_also📖NeuBase Therapeutics60%

see_also📖Microglial Phagocytosis in Neurodegeneration60%

see_also📖Lysosomal Dysfunction in Progressive Supranuclear Palsy60%

see_also📖NeuExo Therapeutics60%

see_also📖Biomarkers for Corticobasal Degeneration60%

see_also📖c1r60%

see_also📖GLP-1 Receptor Agonist Therapeutics Investment Landscape60%

see_also📖Synaptic Dysfunction Pathway60%

see_also📖VTV Therapeutics60%

see_also📖C560%

see_also📖Convelo Therapeutics60%

see_also📖C3AR1 Gene60%

see_also📖Packard Center for ALS Research60%

see_also📖Lyterian Therapeutics60%

see_also📖KCNK2 Gene60%

see_also📖4D Molecular Therapeutics60%

see_also📖Hypoxia Response Pathway60%

see_also📖Dopaminergic Neurons60%

see_also📖Axsome Therapeutics, Inc.60%

see_also📖cynata-therapeutics60%

see_also📖Microbiome-Based Therapeutics for Neurodegeneration: Investm60%

see_also📖Synaptic Dysfunction in Progressive Supranuclear Palsy60%

see_also📖Fulcrum Therapeutics60%

see_also📖PD RNA Therapeutics Companies60%

see_also📖PLA2G6 — Phospholipase A2 Group VI60%

see_also📖Trefoil Therapeutics60%

see_also📖Neuroligin-1 Protein60%

see_also📖TIMP1 Gene60%

see_also📖Lysosomal Dysfunction Therapeutics Investment Landscape60%

see_also📖C5 Protein60%

see_also📖Synaptic Dysfunction in 4R-Tauopathies Comparison60%

see_also📖Alterity Therapeutics60%

see_also📖Hypoxia-Sensitive Dopaminergic Neurons60%

see_also📖Chelsea Therapeutics60%

see_also📖Voyager Therapeutics60%

see_also📖Arvinas Therapeutics60%

see_also📖ITGAM Gene60%

see_also📖Hypoxia Neuroprotection in Sporadic Parkinson's Disease60%

see_also📖Astrocytes60%

see_also📖Anti-Amyloid Therapeutics: Successes, Failures, and Lessons 60%

see_also📖ACSL4 Gene - Acyl-CoA Synthetase Long Chain Family Member 460%

see_also📖Digital Therapeutics for Neurodegenerative Diseases60%

see_also📖Neumora Therapeutics60%

see_also📖Cytochrome Therapeutics60%

see_also📖cyclo-therapeutics60%

see_also📖Biomarkers in Parkinsonian Syndromes (NCT06501469)60%

see_also📖Biomarkers for Multiple System Atrophy60%

see_also📖Adult Neurogenesis Therapeutics Investment Landscape60%

see_also📖Prevail Therapeutics60%

see_also📖Evox Therapeutics60%

see_also📖Mitochondrial Therapeutics60%

see_also📖Inception Therapeutics60%

see_also📖Denali Therapeutics60%

see_also📖Muna Therapeutics60%

see_also📖Reactive Astrocytes (A2 Phenotype)60%

see_also📖dopaminergic-neurons60%

see_also📖Exosome-Based Therapeutics for Neurodegenerative Diseases60%

see_also📖Aleza Therapeutics60%

see_also📖Amyloid-Related Imaging Abnormalities (ARIA)60%

see_also📖Rodin Therapeutics60%

see_also📖Apoptosis in Neurodegeneration60%

see_also📖NOX2/CYBB (NADPH Oxidase 2)60%

see_also📖Pear Therapeutics60%

see_also📖Neurotrophic Factor Therapies for Neurodegenerative Diseases60%

see_also📖RNA Therapeutics: Investment Landscape Analysis60%

see_also📖T3D Therapeutics60%

see_also📖CFB — Complement Factor B60%

see_also📖Synaptic Therapeutics60%

see_also📖Anti-Tau Therapeutics: Investment Landscape Analysis60%

see_also📖Peptide Therapeutics for Neurodegeneration — Investment Land60%

see_also📖Mitochondrial Therapeutics Investment Landscape60%

see_also📖Spin Therapeutics60%

see_also📖Aleza Therapeutics60%

see_also📖Axial Therapeutics60%

see_also📖Encoded Therapeutics60%

see_also📖NeuroMito Therapeutics60%

see_also📖PRKCB — Protein Kinase C Beta60%

see_also📖Synaptic Dysfunction in 4R-Tauopathies60%

see_also📖Synaptic Dysfunction in Parkinson's Disease60%

see_also📖Synaptic Dysfunction in Neurodegeneration60%

see_also📖NLGN1 Gene60%

see_also📖BrainStorm Cell Therapeutics Inc.60%

see_also📖A1 Reactive Astrocytes60%

see_also📖CRISPR Therapeutics60%

see_also📖BlueRock Therapeutics60%

see_also📖Protein Aggregation Inhibitors for Neurodegeneration — Inves60%

see_also📖Lysoway Therapeutics60%

see_also📖Paxos Therapeutics60%

see_also📖Vator Therapeutics Inc.60%

see_also📖Stoke Therapeutics60%

see_also📖Anti-Tau Therapeutics60%

see_also📖Capricor Therapeutics60%

see_also📖Synchronicity Therapeutics60%

see_also📖C1S Gene60%

see_also📖Finch Therapeutics60%

see_also📖astrocyte-neuron-metabolic-coupling-parkinsons60%

see_also📖Lysosomal Dysfunction in Neurodegeneration60%

see_also📖MDS 2026 — Emerging Therapeutics in Parkinson's Disease60%

see_also📖Amyl Therapeutics60%

see_also📖Denali Therapeutics60%

see_also📖Alectos Therapeutics Inc60%

see_also📖Denali Therapeutics60%

see_also📖RNA Editing Therapeutics60%

see_also📖Hypoxia-Sensitive Neurons60%

see_also📖Synaptic Dysfunction in Neurodegenerative Diseases60%

see_also📖Karuna Therapeutics60%

see_also📖Astroglia (Astrocytes)60%

see_also📖Reactive Astrocytes in Neuroinflammation60%

see_also📖pd-exosome-therapeutics60%

see_also📖Resveratrol and Sirtuin Activation for Neurodegeneration60%

see_also📖Synaptic Dysfunction in Corticobasal Syndrome60%

see_also📖Biomarkers for Progressive Supranuclear Palsy60%

see_also📖Synaptic Dysfunction in Neurodegeneration - SfN 2026 Researc60%

see_also📖IFM Therapeutics60%

see_also📖Parkinson's Disease Digital Therapeutics Companies60%

see_also📖AD RNA-Based Therapeutics Companies60%

see_also📖c1q60%

see_also📖Appvian Therapeutics60%

see_also📖AD Exosome and Extracellular Vesicle Companies60%

see_also📖Spark Therapeutics60%

see_also📖Monte Rosa Therapeutics60%

see_also📖Biomarkers in Neurodegeneration60%

see_also📖C1QA Gene60%

see_also📖Heat Shock Protein (HSP) Therapeutics for Neurodegeneration60%

see_also📖Sangamo Therapeutics60%

see_also📖Reactive Astrocytes in Neurodegeneration60%

see_also📖CR3-Dependent Microglial Synapse Elimination in Parkinson&#x60%

see_also📖Ventus Therapeutics60%

see_also📖biomarkers60%

see_also📖Dopaminergic Neurons (SNpc)60%

see_also📖Iduna Therapeutics60%

see_also📖Biomarkers for Parkinson's Disease60%

see_also📖Biomarkers to Distinguish FTLD-tau from FTLD-TDP60%

see_also📖Koneqia Therapeutics60%

see_also📖Synaptic Dysfunction in Alzheimer's Disease60%

see_also📖NOX2 Gene60%

see_also📖BMAL1 (ARNTL) Gene60%

see_also📖Click Therapeutics60%

see_also📖SIRPA Gene60%

see_also📖Anti-Amyloid Therapeutics60%

see_also📖Cerevel Therapeutics60%

see_also📖Lexeo Therapeutics60%

see_also📖dgat160%

see_also📖Pinteon Therapeutics60%

see_also📖4R Tauopathy Therapeutics — Investment Landscape Analysis60%

see_also📖Neteo Therapeutics60%

see_also📖Yumanity Therapeutics60%

see_also📖Alzheimer's Digital Therapeutics Companies60%

see_also📖P2RY1 Gene60%

see_also📖heqIX Therapeutics60%

see_also📖CCL3 Gene60%

see_also📖hypotheses-apoe-contributes-alzheimers-disease-regulat60%

see_also📖ER Stress & UPR Therapeutics Investment Landscape60%

related🔬What are the mechanisms underlying senolytic therapy for age56%

related🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro55%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro55%

mentions🧪Complement C1q Mimetic Decoy Therapy50%

mentions🧪Complement C1q Subtype Switching50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

related🔬Microglia activate astrocytes via IL-1alpha/TNF/C1q, and rea50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying synaptic pruning by micro50%

mentions🧪Temporal TET2-Mediated Hydroxymethylation Cycling50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%

related🔬Cell type vulnerability in Alzheimer's Disease (SEA-AD 50%

mentions🧪Glycine-Rich Domain Competitive Inhibition50%

mentions🧪Cryptic Exon Silencing Restoration50%

mentions🔬What gene expression changes in the aging mouse brain predic50%

related🔬What gene expression changes in the aging mouse brain predic50%

related🔬What are the mechanisms underlying epigenetic clocks and bio50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp50%

related🔬What are the mechanisms underlying synaptic pruning by micro50%

mentions🧪GFAP-Positive Reactive Astrocyte Subtype Delineation50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪Lysosomal Positioning Dynamics Modulation50%

mentions🧪Complement C1QA Spatial Gradient in Cortical Layers50%

mentions🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro50%

mentions🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition50%

mentions🔬What are the mechanisms underlying microglia-astrocyte cross50%

related🔬Neuroinflammation and microglial priming in early Alzheimer&50%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

mentions🧪Cross-Seeding Prevention Strategy50%

mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

mentions🧪PARP1 Inhibition Therapy50%

related🔬What are the mechanisms underlying microglia-astrocyte cross50%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia50%

mentions🧪Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu50%

mentions🧪Trans-Synaptic Adhesion Molecule Modulation50%

mentions🧪Glymphatic System-Enhanced Antibody Clearance Reversal50%

mentions🧪TET2-Mediated Demethylation Rejuvenation Therapy50%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%

related🔬What cell types are most vulnerable in Alzheimer's Dise50%

mentions🔬What are the mechanisms underlying astrocyte reactivity subt50%

mentions🧪TREM2-mediated microglial tau clearance enhancement50%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination50%

related🔬What are the mechanisms underlying astrocyte reactivity subt50%

related🧪Metabolic Circuit Breaker via Lipid Droplet Modulation40%

related🧪Complement C1q Mimetic Decoy Therapy40%

related🧪Lipid Droplet Dynamics as Phenotype Switches40%

related🧪Circadian Rhythm Entrainment of Reactive Astrocytes40%

related🔬What are the mechanisms underlying senolytic therapy for age40%

related🧪Netrin-1 Gradient Restoration40%

related🧪Mechanosensitive Ion Channel Reprogramming40%

related🔬What gene expression changes in the aging mouse brain predic40%

related🧪SASP-Mediated Cholinergic Synapse Disruption40%

related🧪Senescent Cell Mitochondrial DNA Release40%

related🔬PSP and CBD both involve 4R-tau but produce distinct neuropa40%

related🧪Synthetic Biology Rewiring via Orthogonal Receptors40%

related🧪Mitochondrial Transfer Pathway Enhancement40%

related🧪Oligodendrocyte White Matter Vulnerability40%

related🧪Aquaporin-4 Polarization Rescue40%

related🔬What are the mechanisms underlying astrocyte reactivity subt40%

related🧪Metabolic Switch Targeting for A1→A2 Repolarization40%

related🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro40%

related🧪Quantum Coherence Disruption in Cellular Communication40%

related🧪Sphingolipid Metabolism Reprogramming40%

mentions🔬Microglia activate astrocytes via IL-1alpha/TNF/C1q, and rea40%

related🧪SASP-Driven Aquaporin-4 Dysregulation40%

related🧪TFEB-PGC1α Mitochondrial-Lysosomal Decoupling40%

related🧪Microglial Purinergic Reprogramming40%

related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%

related🧪TREM2-Dependent Microglial Senescence Transition40%

related🧪Extracellular Matrix Stiffness Modulation40%

related🧪Complement C1q Subtype Switching40%

related🧪Biorhythmic Interference via Controlled Sleep Oscillations40%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%

related🧪Senescence-Activated NAD+ Depletion Rescue40%

mentions🔬Analyze circuit-level changes in neurodegeneration using All40%

related🔬Gene expression changes in aging mouse brain predicting neur40%

related🧪Epigenetic Memory Erasure via TET2 Activation40%

related🧪Age-Dependent Complement C4b Upregulation Drives Synaptic Vu40%

related🧪Complement-Mediated Synaptic Pruning Dysregulation40%

mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%

related🧪Purinergic Signaling Polarization Control40%

related🔬Microglia activate astrocytes via IL-1alpha/TNF/C1q, and rea40%

related🧪Phase-Separated Organelle Targeting40%

related🧪Senescence-Induced Lipid Peroxidation Spreading40%

related🧪Senescence-Associated Myelin Lipid Remodeling40%

related🔬Senolytics targeting p16/p21+ senescent astrocytes and micro40%

related🧪Oligodendrocyte White Matter Vulnerability40%

related🔬What are the mechanisms underlying microglia-astrocyte cross40%

related🧪Glial Glycocalyx Remodeling Therapy40%

related🧪Ephrin-B2/EphB4 Axis Manipulation40%

related🧪Trans-Synaptic Adhesion Molecule Modulation40%

related🧪Temporal Decoupling via Circadian Clock Reset40%

related🧫bEV-mediated synaptic pruning via C1q-C3 pathway33%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp24%

C3 — Complement Component 3

💬 Discussion